Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 4/20 | 0.39 |
| ▸ | ADH1A | P07327 | 4/20 | 0.39 |
| ▸ | ADH7 | P40394 | 4/20 | 0.39 |
| ▸ | ADH1C | P00326 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063617 | 0.86 | ADH1B (0.43) | TP53ADH1BADH1AADH7ADH1C | |
| SCHEMBL28917637 | 0.76 | TP53 (0.42) | TP53HPGDALDH1A1TSHRHSD17B10 | |
| SCHEMBL4470088 | 0.74 | TBXAS1 (0.52) | ALDH1A1HSD17B10 | |
| SCHEMBL4042725 | 0.73 | DAO (0.38) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL21987085 | 0.72 | — | — | |
| SCHEMBL7717133 | 0.68 | HIF1A (0.43) | TP53TSHR | |
| SCHEMBL11483792 | 0.68 | CYP2C19 (0.38) | TP53HPGDALDH1A1TSHR | |
| SCHEMBL17733804 | 0.67 | — | — | |
| SCHEMBL1680682 | 0.67 | — | — | |
| SCHEMBL4033337 | 0.67 | TP53 (0.39) | TP53HPGDALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-4188389-A | 1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines | AYERST MCKENNA & HARRISON, INC. (CA) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TP53 349/4885ADH1B 3772/4885ADH1A 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.